Live Breaking News & Updates on Markus Manns

Stay updated with breaking news from Markus manns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Health: Blockbuster obesity drug demand drives Novo Nordisk profit boost

Health: Blockbuster obesity drug demand drives Novo Nordisk profit boost
gdnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gdnonline.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Lars Fruergaard Jorgensen , Karsten Munk Knudsen , Eli Lilly , Markus Manns , Jyske Bank , Novo Holdings , Union Investment , Us Federal Trade Commission , Novo Nordisk , Fruergaard Jorgensen , Chief Financial Officer Karsten Munk Knudsen , Trade Commission ,

Novo Nordisk raises outlook fuelled by obesity drug demand By Reuters

Novo Nordisk raises outlook fuelled by obesity drug demand By Reuters
investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.

United States , City Of , United Kingdom , Eli Lilly , Lars Fruergaard Jorgensen , Karsten Munk Knudsen , Maggie Fick , Markus Manns , Union Investment , Novo Nordisk , Fruergaard Jorgensen , Chief Financial Officer Karsten Munk Knudsen ,

Bayer investors weigh need for cash call amid stifling debt

Bayer may have
to ask shareholders for fresh capital to shore up its finances
even after the debt-laden German drugmaker slashed dividends
last week in its latest effort to get wiggle room,. ....

Markus Manns , Julius Baer , Josephine Mason , Fabian Wenner , Bill Anderson , Martin Schnee , Ludwig Burger , Christina Fincher , Werner Baumann , Patricia Weiss , Union Investment ,

Analysis-Bayer investors weigh need for cash call amid stifling debt

Bayer may have to ask shareholders for fresh capital to shore up its finances even after the debt-laden German drugmaker slashed dividends last week in its latest effort to get wiggle room, analysts said. But new CEO Bill Anderson may struggle to win over investors, who have seen the company's value sink by two thirds since its $63 billion acquisition of Monsanto in 2018, which saddled it with costly litigation and debt. The debate over a possible share issue comes as Anderson, who was hired last June to revive the company's fortunes, prepares to deliver a strategic investor update in London on Tuesday. ....

Christina Fincher , Patricia Weiss , Werner Baumann , Martin Schnee , Bill Anderson , Ludwig Burger , Josephine Mason , Fabian Wenner , Markus Manns , Julius Baer , Union Investment , Capital Increase , Martin Schnee , Ostly Litigation ,